Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis

被引：0
作者：
Bernard Combe
Robin Besuyen
Antonio Gómez-Centeno
Tsukasa Matsubara
Juan José Sancho Jimenez
Zhaoyu Yin
Maya H. Buch
机构：
[1] University of Montpellier,NIHR Manchester Biomedical Research Centre
[2] Galapagos BV,undefined
[3] Hospital Universitari Parc Tauli,undefined
[4] Sabadell,undefined
[5] Matsubara Mayflower Hospital,undefined
[6] Galapagos,undefined
[7] Gilead Sciences,undefined
[8] Inc.,undefined
[9] University of Manchester,undefined
来源：
Rheumatology and Therapy | 2023年 / 10卷
关键词：
Adverse effects; Disease-modifying antirheumatic drug; Filgotinib; Outcomes; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Clinical trials in rheumatoid arthritis recruit too few patients from diverse ethnic backgrounds to be able to identify differences in treatment outcomes. In adults with moderate-to-severe active rheumatoid arthritis who do not tolerate or have responded poorly to other advanced treatments, the Janus kinase inhibitor filgotinib can be used alone or in combination with the immunosuppressant methotrexate. Using data from 4695 patients with rheumatoid arthritis from five previous clinical trials and two ongoing trial extensions, this paper examined the efficacy and safety of filgotinib in patients with rheumatoid arthritis across geographic locations worldwide.
引用
收藏
页码：35 / 51
页数：16
相关论文
共 104 条
[1]  
Safiri S(2019)Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017 Ann Rheum Dis 78 1463-1471
[2]  
Kolahi AA(2021)The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review Rheumatol Int 41 863-877
[3]  
Hoy D(2021)A review of the prevalence and unmet needs in the management of rheumatoid arthritis in Africa and the Middle East Rheumatol Ther 8 1-16
[4]  
Almutairi K(2010)Geoepidemiology of autoimmune rheumatic diseases Nat Rev Rheumatol 6 468-476
[5]  
Nossent J(2012)Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline Arthritis Care Res (Hoboken) 64 1135-1143
[6]  
Preen D(2013)Current therapies in rheumatoid arthritis: a Latin American perspective Reumatol Clin 9 106-112
[7]  
Keen H(2020)Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials Rheumatology (Oxford) 59 3023-3031
[8]  
Inderjeeth C(2019)Demographic characteristics of participants in rheumatoid arthritis randomized clinical trials: a systematic review JAMA Netw Open 2 1195-1196
[9]  
Almoallim H(2014)Rheumatoid arthritis in the developing world: stepping up to the challenge Clin Rheumatol 33 1345580-749
[10]  
Al Saleh J(2017)Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region J Mark Access Health Policy 5 741-858
12345678910